China is gaining a solid reputation as a pharmaceutical innovation hub, shifting from a copycat drug maker to one whose…
Read More »Hansoh
The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants…
Read More »
Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring…
Read More »